We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
David Reardon

David A Reardon MD

Professor of Medicine, Harvard Medical School; Clinical Director, Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts

Dr. David A. Reardon is Clinical Director of the Center for Neuro-Oncology at the Dana-Farber Cancer Institute in Boston and previously served as the Associate Deputy Director of the Preston Robert Tisch Brain Tumor Center at Duke University Medical Center for 11 years. Dr. Reardon is an active researcher with special interests in the design and implementation of clinical trials for neuro-oncology and the preclinical evaluation of promising therapeutics for central nervous system tumors. His work includes using innovative clinical therapeutic agents to improve cure rates in patients with brain and spinal tumors, with particular focus on immunotherapeutics as well as molecular-targeting agents, anti-angiogenic reagents, cytotoxins, and other biologically based therapies.

Dr. Reardon was awarded his medical degree by Tufts University School of Medicine in Boston. He completed his residency at Johns Hopkins Hospital in Baltimore and was awarded a fellowship in pediatric hematology-oncology at the University of Michigan.

Dr. Reardon has published over 170 peer-reviewed manuscripts and received the R. Wayne Rundles Award for Excellence in Cancer Research. In 2013, he was elected as the tenth president of the Society for Neuro-Oncology.